As a treatment of noninvasive,safe,effective,and easy to operate,external counterpulsation has been widely used in the treatment of ischemic heart disease.The treatment mechanism of external counterpulsation may improve collateral circulation and hemodynamics.Therefore,it can provide a new measure for the treatment of cerebrovascular disease.However,the efficacy and safety of external counterpulsation in the treatment of ischemic stroke still need to be confirmed by a large sample clinical trial.

We prepared gold nanostar (GNS) through seed growth method firstly,then formation of COX-2 siRNA(siCOX-2) and GNS composite modified with polyethylene glyco (PEG),2-amino-2-deoxy-D-glucos (DG) and 9-D-arginin (9R) was prepared.Mterwords,paclitaxel temperature sensitive liposome (PTX-TSL) was prepared by film dispersion method.Finally,siCOX-2 delivery systerm (PTX-TSL-(siCOX-2(9R/DG-GNS)))was obtained by hydrosulfuryl ligand reaction between siCOX-2 (9R/DG-GNS) and PTX-TSL The successful build of siCOX-2 (9R/DG-GNS) was vetified by nuclear magnetic resonance (NMR),sodium dodecyl sulfate polyacryl amide gel electrophoresis (SDS-PAGE),and ultraviolet spectrophotometry and agarose gel electrophoresis method.Particle size of PTX-TSL-(siCOX-2(9R/DG-GNS)) was (292 ± 14) nm and Zeta potential was about -(2.59 ± 0.12) mV,which were measured by Zetasizer Nano ZS90.The morphology of PTX-TSL-(siCOX-2 (9R/DG-GNS)) measured by transmissionelectronmicroscopy showed homogeneous star structure with phospholipid bilayer on the surface,and it showed good thermal conversion efficiency under radiation of 808 nm laser.Differential scanning calorimetry test showed that PTX-TSL phase transition temperature is about 42.6 ℃.The drug loading content(using dialysis method) and encapsulation efficiency of PTX-TSL were about 7.5％ and 95.4％,at the same time,the release process experiment of PTX-TSL showed that it had a good temperature sensitive release performance.It is hopeful that this siCOX-2 system can be used for reducing drug resistance of PTX and improving the treatment effect of PTX through the synergistic antitumor drug resistance effect of siCOX-2.

【Objective】 To investigate the role of lipopolysaccharide (LPS) in regulating the inflammatory response of neutrophil through the leucine-rich α-2 glycoprotein 1 (LRG1)/ Rho-associated protein kinase (ROCK1) signaling. 【Methods】 HL-60 cells were treated with 1 μmol/L all-trans retinoic acid (ATRA) and 12.5 μL/mL dimethyl sulfoxide (DMSO) for 72 h and 96 h, and the morphological changes were observed by Wright-Giemsa staining. The expression of CD11b was detected by flow cytometry. LPS induced the activation of dHL-60 and human peripheral blood neutrophils. The transcription and secretion levels of LRG1, ROCK1 and inflammatory cytokines were detected by qPCR and ELISA, respectively. The expression levels of LRG1 and ROCK1 after the activation of dHL-60 were detected by Western blotting. Furthermore, dHL-60 was treated with the recombinant protein LRG1 and ROCK1 inhibitor Y-27632; the transcription levels of inflammatory cytokines were detected by qPCR. 【Results】 Neutrophils were activated by LPS. The expression levels of LRG1 and ROCK1 were significantly increased, and the transcription levels of inflammatory cytokines were significantly increased. The recombinant protein LRG1 activated dHL-60 in vitro, and the transcription levels of ROCK1 and inflammatory cytokines were significantly increased. Using the ROCK1 inhibitor Y-27632, the production levels of inflammatory cytokines were significantly reduced. 【Conclusion】 LPS can regulate the production levels of neutrophil inflammatory cytokines through activating the LRG1/ROCK1 signaling, thus exacerbating the inflammatory response.